ScripWith understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the com
ScripScrip regularly reviews technology transfer activity across the biopharmaceutical sector. This edition of Tech Transfer Roundup focuses on oncology deals; the next edition will look at non-oncology de
ScripBridgeBio Pharma, Inc. employs a business model of acquiring rights to or partnering with academic and institutional research in monogenic diseases and genetic cancer indications, often forming singl
ScripThe biopharma industry has high ambitions to improve therapies for patients across many disease categories, drawing on a wealth of technological advances that have been emerging and maturing in recent